Parallel processing in neural systems and computers / by Eckmiller, Rolf, Hartmann, George, Hauske, Gert

Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes by Gregory A. Nichols, Anouk Derúaz-Luyet, Kimberly G. Brodovicz, Teresa M. Kimes, A. Gabriela Rosales, Sibylle J. Hauske

Get full text

Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diab... by Gregory A. Nichols, Anouk Déruaz-Luyet, Kimberly G. Brodovicz, Teresa M. Kimes, A. Gabriela Rosales, Sibylle J. Hauske

Get full text

Monoclonal Antibody RYSK173 Recognizes the Dinuclear Zn Center of Serum Carnosinase 1 (CN-1): Possible Consequences of Zn Binding for CN-1 Recognition by RYSK173. by Shiqi Zhang, Holger A Lindner, Sarah Kabtni, Jaap van den Born, Stephan Bakker, Gerjan Navis, Bernard Krämer, Benito Yard, Sibylle Hauske

Get full text

Lipopolysaccharide Tolerance in Human Primary Monocytes and Polarized Macrophages by Hui Li, Annette Breedijk, Nadine Dietrich, Katja Nitschke, Jonas Jarczyk, Philipp Nuhn, Bernhard K. Krämer, Benito A. Yard, Jan Leipe, Sibylle Hauske

Get full text

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study by Herrington, W, Preiss, D, Haynes, R, von Eynatten, M, Staplin, N, Hauske, S, George, J, Green, J, Landray, M, Baigent, C, Wanner, C

Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY by Nangaku, M, Herrington, WG, Goto, S, Maruyama, S, Kashihara, N, Ueki, K, Wada, J, Watada, H, Nakashima, E, Lee, R, Massey, D, Mayne, KJ, Tomita, A, Haynes, R, Hauske, SJ, Kadowaki, T

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial by Judge, PK, Tuttle, KR, Staplin, N, Hauske, SJ, Zhu, D, Sardell, R, Cronin, L, Green, JB, Agrawal, N, Arimoto, R, Mayne, KJ, Sammons, E, Brueckmann, M, Shah, SV, Rossing, P, Nangaku, M, Landray, MJ, Wanner, C, Baigent, C, Haynes, R, Herrington, WG

Empagliflozin in patients with chronic kidney disease by Herrington, WG, Staplin, N, Green, JB, Hauske, SJ, Emberson, J, Preiss, D, Judge, P, Mayne, K, Ng, S, Sammons, E, Zhu, D, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Wen Liu, Kadowaki, T, Nangaku, M, Levin, A, Cherney, D, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Petrini, M, Massey, D, Eilbracht, J, Brueckmann, M, Landray, M, Baigent, C, Haynes, R

Long-term effects of empagliflozin in patients with chronic kidney disease by Herrington, WG, Staplin, N, Agrawal, N, Wanner, C, Green, JB, Hauske, SJ, Emberson, JR, Preiss, D, Judge, P, Zhu, D, Dayanandan, R, Arimoto, R, Mayne, KJ, Ng, SYA, Sammons, E, Hill, M, Stevens, W, Wallendszus, K, Brenner, S, Cheung, AK, Liu, Z-H, Li, J, Hooi, LS, Liu, W, Kadowaki, T, Nangaku, M, Levin, A, Cherney, DZI, Maggioni, AP, Pontremoli, R, Deo, R, Goto, S, Rossello, X, Tuttle, KR, Steubl, D, Massey, D, Brueckmann, M, Landray, MJ, Baigent, C, Haynes, R